Onyx on a roll with multiple myeloma drug, wins US FDA fast track
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals initiated a rolling submission to the US FDA of a new drug application (NDA) for the firm's next-generation proteasome inhibitor carfilzomib after the agency granted fast-track designation to the experimental compound. This puts the firm in line for a potential approval before the end of the year.